You are here
Phase 2 Trial of VLTS-934 Initiated in Peripheral Arterial Disease
In this randomized, double-blinded and placebo-controlled trial, approximately 148 patients with peripheral arterial disease, specifically intermittent claudication, will receive either VLTS-934 or a saline placebo. The primary endpoint of the trial is improvement in exercise tolerance. Valentis plans to complete enrollment in the first quarter of 2006 and data are expected mid-2006.
This VLTS-934 Phase IIb trial follows a previously completed 105 patient Phase IIa clinical trial that compared VLTS-934 to an investigational angiogenic agent. In that trial, VLTS-934 demonstrated a statistically significant improvement in exercise tolerance and ankle-brachial index compared to baseline. The Phase IIb trial has a virtually identical design to the Phase IIa trial but includes a comparison to patients treated with a saline placebo.
The estimated market for a safe and efficacious product to treat intermittent claudication is in excess of $1 billion. Approximately five percent of adults in the United States over the age of 55 suffer from the intermittent claudication, a form of peripheral arterial disease. Symptoms of intermittent claudication include leg pain during exercise due to a lack of adequate blood flow.
Source: Valentis, Inc.